As GR is a ubiquitous steroid hormone receptor, pS134-GR may function similarly in other endocrine-related and/or highly metastatic forms of neoplasia (i.e., prostate cancer, ovarian cancer, melanoma). This evidence concerns the gene NR3C1 and ovarian carcinoma.